Phenylketonurias Clinical Trial
Official title:
A Preliminary Study of the Neurological and Neuropsychological Effects of Palynziq-Related Changes in Phenylalanine in Individuals With Phenylketonuria (PKU)
The goal of the proposed study is to elucidate neurologic and neuropsychological improvements associated with Palynziq-related reduction in plasma Phe levels in individuals with PKU. To this end, investigators will utilize state-of-the-art neuropsychological and multi-modal neuroimaging methods to examine the effects of large Phe level reduction (levels <360 μmol/L for at least 3 consecutive months) on GM and WM brain structures, brain concentrations of Phe, functionality of brain networks, and associated cognitive functioning in a sample of individuals with PKU who are being treated with Palyzniq.
Past studies have documented PKU-related disruptions in brain phenylalanine (Phe) levels, white matter (WM) and gray matter (GM) brain structures, functional connectivity, and neurocognitive functioning. Additional research suggests that the disruptive effects of excessive blood Phe levels likely contribute to these abnormalities, and treatment aimed at lower Phe levels may lead to significant improvements. Within this context, the primary aim is to test the hypotheses that Palynziq-related reductions in blood Phe levels will be associated with: 1. A decrease in brain Phe levels as measured by magnetic resonance spectroscopy (MRS). 2. A decrease in the extent and severity of WM abnormalities as evidenced by increased mean diffusivity values - a measure of microstructural WM integrity that is derived via diffusion-weighted magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI). 3. Closer-to-normal volumetric measurements for GM structures. Nature of this effect will be dependent on structure. For example, PKU is associated with increased volume in basal ganglia but decreased volume in posterior cortex and cerebellum (Aldridge et al., 2020; Bodner et al., 2012; Christ et al., 2016). 4. An increase in functional connectivity within the brain's functional networks as measured by resting state functional MRI (fMRI). 5. Improved performance on neurocognitive tests of executive function, attention, processing speed, and motor control. To accomplish this aim, a total sample of up to 13 adults with PKU who have previously completed baseline (pre-Palnyziq) neurocognitive and neuroimaging evaluations will be recruited from the two sites (University of Missouri, Boston Children's Hospital). Participants will be reassessed following a significant and prolonged Phe response to Palynziq (as reflected by at least 3 consecutive months of Phe levels below 360 μmol/L). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05998109 -
PheCheck Feasibility Study
|
||
| Not yet recruiting |
NCT04433728 -
Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.
|
||
| Completed |
NCT01209819 -
Bone Mineral Density in Adults With Hyperphenylalaninemia
|
N/A | |
| Active, not recruiting |
NCT05174559 -
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
|
N/A | |
| Not yet recruiting |
NCT04969809 -
Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients
|
N/A | |
| Recruiting |
NCT04404530 -
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
|
||
| Recruiting |
NCT05827536 -
Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU.
|
N/A | |
| Active, not recruiting |
NCT05971563 -
Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers
|
N/A | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Completed |
NCT04368624 -
PKU Skin Stripping
|
||
| Completed |
NCT04452513 -
A Prospective Clinical Study of Phenylketonuria (PKU)
|
||
| Completed |
NCT05497050 -
The Effect of Nursing Empowerment Program
|
N/A | |
| Completed |
NCT04943393 -
Remote Neurocognitive and Psychological Assessment in PKU
|
||
| Completed |
NCT05096988 -
Evaluation of PKU Sphere Liquid
|
N/A | |
| Completed |
NCT00225615 -
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
|
Phase 3 | |
| Recruiting |
NCT05128149 -
Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
|
||
| Terminated |
NCT05229549 -
Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria
|
N/A | |
| Not yet recruiting |
NCT06332807 -
AAV Gene Therapy Clinical Study in Adult Classic PKU
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06337864 -
Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria
|
N/A | |
| Completed |
NCT02445521 -
Testing of Four Home Phenylalanine Monitoring Prototype Devices
|
N/A |